EXAS Cologuard: תחזית צמיחת רווחים לשנה הבאה

Exact Sciences aims for global leadership in early cancer detection through the expansion of home tests and liquid biopsies. This chart in the GURU.Markets terminal illustrates the expected growth in earnings per share for next year, where the figure stood at 1890.10. This confirms revenue stability driven by insurance reimbursements, while logistics optimization via outsourcing reduces the burden on laboratories.

The fundamental value of shares depends directly on the expected dynamics of net earnings per share. This indicator measures the percentage change in EPS, reflecting the analysts' consensus forecast for the business's future profitability. By analyzing the growth rate model for the coming year, an investor assesses the sustainability of cash flows. For Exact Sciences (EXAS), this trend confirms the effectiveness of its expansion into the liquid biopsy and at-home screening segments.